ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1655

Plasma microRNA Expression Profiles in Ankylosing Spondylitis Patients

Pilar Font-Ugalde1, Carlos Perez-Sanchez1, Chary Lopez-Pedrera1, M. Carmen Castro-Villegas2, Maria Carmen Abalos-Aguilera3, Patricia Ruiz-Limon3, Nuria Barbarroja1, Ivan Arias de la Rosa3, Rafaela Ortega-Castro1, Alejandro Escudero-Contreras3, Eduardo Collantes-Estévez1 and Yolanda Jiménez-Gómez1, 1Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 3Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Ankylosing spondylitis (AS) and biomarkers, MicroRNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  MicroRNAs (miRNAs) are a group of single-stranded non-coding RNAs of 20-25 nucleotides in length that can potentially regulate every aspect of cellular function. Recent studies have demonstrated that miRNAs can be detected in the circulation and serve as potential biomarkers of various diseases. Our aim was to evaluate whether AS pathogenesis is related to the aberrant expression of plasma miRNAs.

Methods: The expression profile of 800 miRNAs was determined in pooled RNA samples from plasma of AS patients and healthy donors (HDs) (n=3 each) using a nCounter miRNA assay. Next, candidate miRNAs were validated by real time RT-PCR in a validation cohort of 26 AS patients and 26 HDs. To evaluate their relevance in the AS pathogenesis, an analysis was carried out by using the web-based bioinformatics tool IPA. Association studies with the clinical status of the AS patients were also performed. AS activity was defined as BASDAI ≥ 4, CRP > 8 mg/L and ESR > 20 mm/h. Structural damage was evaluated by mSASSS.

Results:  In discovery phase, nine miRNAs were differentially expressed (fold change ≥ 2) in the plasma of AS patients vs. HDs. After validation, seven of the nine miRNAs clearly distinguished AS plasma samples with high confidence level (P < 0.05). Specifically, the circulating levels of miR-146a-5p, miR-125a-5p, and miR22-3p were upregulated, whereas those of miR-320e, miR-151-3p, miR150-5p and miR-451a were downregulated in AS patients vs. HDs. The ROC curve analyses of these miRNAs exhibited a moderate distinguishing efficiency, with the AUCs for these miRNA ranging from 0.674 to 0.746. In addition, target gene prediction by IPA analysis showed that these altered miRNAs were involved in affecting various aspect of AS, such as signaling pathways related to inflammatory response and bone turnover. Association studies showed that plasma miR-146a-5p expression was significantly increased in active AS patients as compared with non-active AS patients (P = 0.037). In addition, we observed that AS patients with higher structural damage exhibited significantly lower miR-151-3p expression than those with less radiographic severity (P = 0.045); the ROC curve analyses showed that relative expression of this miRNA could distinguish AS patients with radiographic severity, with a power AUC of 0.761 (P= 0.05).

Conclusion:  This study has identified a set of circulating miRNAs which could be attractive candidates as noninvasive biomarkers for the diagnosis of AS patients and may help elucidate the pathogenesis of AS. Funded by PI-0314-2012, SER


Disclosure: P. Font-Ugalde, None; C. Perez-Sanchez, None; C. Lopez-Pedrera, None; M. C. Castro-Villegas, None; M. C. Abalos-Aguilera, None; P. Ruiz-Limon, None; N. Barbarroja, None; I. Arias de la Rosa, None; R. Ortega-Castro, None; A. Escudero-Contreras, None; E. Collantes-Estévez, None; Y. Jiménez-Gómez, None.

To cite this abstract in AMA style:

Font-Ugalde P, Perez-Sanchez C, Lopez-Pedrera C, Castro-Villegas MC, Abalos-Aguilera MC, Ruiz-Limon P, Barbarroja N, Arias de la Rosa I, Ortega-Castro R, Escudero-Contreras A, Collantes-Estévez E, Jiménez-Gómez Y. Plasma microRNA Expression Profiles in Ankylosing Spondylitis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/plasma-microrna-expression-profiles-in-ankylosing-spondylitis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-microrna-expression-profiles-in-ankylosing-spondylitis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology